Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2021 | $5.50 → $5.00 | Buy | HC Wainwright & Co. |
| 7/16/2021 | $7.00 | Buy | Truist Securities |
EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares' corporate Human Resources ("HR") strategy and development. Claude E. Richardson has more than 25 years of Human Resources leadership experience across multiple industries including pharmaceutical, industrials, financial services and consumer products. His broad-based background in Human Resources includes talent management and acquisition, compensation and benefits, development and training, performance manage
EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies. Since 2018, she has served as the Chief Financial Officer of NatureWorks, LLC. Prior to that, she was the Chief Financial Officer at NxThera, Inc. From 2002 to 2012, she also served as the Chief Financial Officer of Tornier, NV, Spine Wave, Inc. and American Medical Systems, I
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) ("the Company"), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests. Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institut
HC Wainwright & Co. reiterated coverage of Antares Pharma with a rating of Buy and set a new price target of $5.00 from $5.50 previously
Truist Securities initiated coverage of Antares Pharma with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. reiterated coverage of Antares Pharma with a rating of Buy and set a new price target of $5.00 from $4.50 previously
Submission status for ANTARES PHARMA INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form
CHICAGO, May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D., to the board of directors and Chris Ehrlich as Senior Advisor. Dr. Wotton fills the role of Independent Director of the Board, created following Dimension's Series A raise of $15M completed in February 2023. He brings an expert perspective on platform growth opportunities as a leader of multiple global biotechnology and pharmaceutical companies. Dr. Wotton is a serial entrepreneur and inventor with experience spanning scientific research, product development, and transformational busines
SAN DIEGO, May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), applicable to Halozyme's proposed acquisition of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") has expired. On April 26, 2022, Halozyme commenced a tender offer (the "Offer") to purchase all outstanding shares of common stock of Antares (the "Shares") for $5.60 per share in cash, without interest thereon and net of any applicable withholding taxes. As a result of the expiration of the waiting period under the HSR Act, the condition to the Offer relating to the expirat
SAN DIEGO, April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement"). The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May [23], 2022, unless extended in accordance with the terms of
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which exclu
EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) (the "Company"), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The conference ID number is 9589807. A live webcast and replay of the conference call will be available online from the investor relations section of the Antares Pharma corporate website at www.antares
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
4 - ANTARES PHARMA, INC. (0001016169) (Issuer)
SC 13G - ANTARES PHARMA, INC. (0001016169) (Subject)
SC 13G - ANTARES PHARMA, INC. (0001016169) (Subject)
15-12B - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
EFFECT - ANTARES PHARMA, INC. (0001016169) (Filer)
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter. Antares Pharma earned $32.68 million, and sales totaled $48.73 million in Q4. Why Is ROIC Significant? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q1, Antares Pharma posted an ROIC of -1.44%. Keep in mind, w
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to purchase all outstanding shares of common stock of Antares Pharma, Inc. (NASDAQ:ATRS) ("Antares") for $5.60 per share in cash. The offer is being made pursuant to the previously announced Agreement and Plan of Merger, dated as of April 12, 2022, by and among Halozyme, Purchaser and Antares (the "Merger Agreement"). The tender offer is scheduled to expire at one minute past 11:59 p.m. Eastern Time, on May [23], 2022, unless extended in accordance with the terms of the Merger Agreement. The closing of the
Upgrades For United Parcel Service Inc (NYSE:UPS), Loop Capital upgraded the previous rating of Hold to Buy. For the fourth quarter, United Parcel Service had an EPS of $3.59, compared to year-ago quarter EPS of $2.66. The stock has a 52-week-high of $233.72 and a 52-week-low of $174.70. At the end of the last trading period, United Parcel Service closed at $188.87. According to WestPark Capital, the prior rating for Paysafe Ltd (NYSE:PSFE) was changed from Hold to Buy. The stock has a 52-week-high of $14.30 and a 52-week-low of $2.58. At the end of the last trading period, Paysafe closed at $3.25. Baird upgraded the previous rating for H.B. Fuller Co (NYSE:FUL) from Neutral to Outperf